News

This acceptance follows submission of the MAA in December 2017. GW CEO Justin Gover said: “The successful filing of the MAA for Epidiolex with the EMA builds on

PFS is one of the two co-primary endpoints of the trial, dubbed CheckMate -227. Overall survival (OS) is the other endpoint. The phase 3 trial had assessed the

PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors,

Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) antibody, which is intended to be given as a quarterly or monthly injection. The CGRP ligand is known to be a

The grant is from Innovate UK's Medicines Manufacturing Round 1: Challenge Fund, which itself is funded through the UK Government's £70m Industrial Strategy Challenge Fund to speed up

Leukine is an immuno-stimulant that advances the growth and activation of a wide range of white blood cells, which activate the body's immune response to battle infections. PTx

It was approved to treat HABP/VABP caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae

The new company, named as Theramex, will manufacture products focused on women and their health. Theramex includes Teva’s formerly-owned women’s health product portfolio across contraception, fertility, menopause and

Under the terms of the agreement, Syndax and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in multiple solid tumor types.